Wayne Cannon
Optometrist · Columbia, SCNPI 1801861836
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 109 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations. Among optometrist clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 109 payments — averaging $65.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$1K
- Alcon$859
- Bausch & Lomb Americas Inc.$843
- AbbVie$717
- Coopervision Inc.$523
- Sight Sciences, Inc.$376
- plus $3K from 19 others
What the payments were for
- Food & beverage$6,92997%
- Entertainment$2023%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 36 | $1,102 |
| Alcon | 11 | $859 |
| Bausch & Lomb Americas Inc. | 10 | $843 |
| AbbVie(2 entities) | 7 | $717 |
| Coopervision Inc. | 5 | $523 |
| Sight Sciences, Inc. | 4 | $376 |
| Oyster Point Pharma, Inc. | 10 | $342 |
| Biotissue Holdings Inc. | 2 | $301 |
| Amgen | 2 | $250 |
| Tarsus Pharmaceuticals, Inc. | 2 | $242 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $205 |
| Optos, Inc. | 2 | $202 |
| Johnson & Johnson Vision Care, Inc. | 2 | $140 |
| Glaukos Corporation | 1 | $135 |
| Maculogix, Inc. | 1 | $126 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $124 |
| Novartis | 1 | $119 |
| Mallinckrodt Hospital Products Inc. | 1 | $112 |
| LKC Technologies, Inc. | 1 | $98 |
| Alcon Research LLC | 1 | $85 |
| Rxsight Inc | 1 | $79 |
| Dompe US, Inc. | 1 | $57 |
| Kala Pharmaceuticals, Inc. | 3 | $48 |
| Carl Zeiss Meditec USA, Inc. | 1 | $27 |
| Thea Pharma Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CEQUA$618
- TOTAL30$278
- TEPEZZA$250
- Tecnis IOL$248
- XDEMVY$242
- INFUSE$236
- MIEBO$223
- XIIDRA$223
- Clariti Contact Lens$218
- OMNI(R) SURGICAL SYSTEM (US)$210
- P200DTx$202
- P200T$202
- P200TE$202
- P200TxE$202
- TEARCARE SYSTEM$150
- Prokera$146
- AmnioGraft$146
- Clareon$138
- KXL System$135
- Photrexa$135
How this compares
$7,132 in reported general payments places this provider in the 95th percentile of 653 optometrist providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TyrvayaVarenicline Tartrate | 21 | $13,356 |
| XiidraLifitegrast | 17 | $11,439 |
| Lotemax SmLoteprednol Etabonate | 15 | $4,200 |
| LumiganBimatoprost | 11 | $2,675 |
| Latanoprost | 18 | $233 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Oyster Point Pharma, Inc.Tyrvaya | $342 | $13,35621 claims |
| Bausch & Lomb Americas Inc.Xiidra | $843 | $11,43917 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm | $205 | $4,20015 claims |
| AbbVieLumigan | $717 | $2,67511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 653 optometrist providers in South Carolina.
Other optometrist in Columbia
- Patrick VollmerColumbia$49K
- Nickolas VastisColumbia$7K
- Bradley PowersColumbia$7K
- Dorothy ParkColumbia$6K
- Philip FlynnColumbia$5K
- John BrinkleyColumbia$5K
- Thomas WeshefskyMyrtle Beach$77K
- Richard BedellCharleston$55K
- William ColemanEasley$22K
- Furman SmithMt Pleasant$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.